Download or read book Computational Modeling of Drugs Against Alzheimer s Disease written by Kunal Roy and published by Springer Nature. This book was released on 2023-06-30 with total page 492 pages. Available in PDF, EPUB and Kindle. Book excerpt: This second edition volume expands on the previous edition with updated descriptions on different computational methods encompassing ligand-based, structure-based, and combined approaches with their recent applications in anti-Alzheimer drug design. Different background topics like recent advancements in research on the development of novel therapies and their implications in the treatment of Alzheimer’s Disease (AD) have also been covered for completeness. Special topics like basic information science methods for insight into neurodegenerative pathogenesis, drug repositioning and network pharmacology, and online tools to predict ADMET behavior with reference to anti-Alzheimer drug development have also been included. In the Neuromethods series style, chapter include the kind of detail and key advice from the specialists needed to get successful results in your laboratory. Cutting-edge and thorough, Computational Modeling of Drugs Against Alzheimer’s Disease, Second Edition is a valuable resource for all researchers and scientists interested in learning more about this important and developing field.

Download or read book Current Trends in Computational Modeling for Drug Discovery written by Supratik Kar and published by Springer Nature. This book was released on 2023-06-30 with total page 311 pages. Available in PDF, EPUB and Kindle. Book excerpt: This contributed volume offers a comprehensive discussion on how to design and discover pharmaceuticals using computational modeling techniques. The different chapters deal with the classical and most advanced techniques, theories, protocols, databases, and tools employed in computer-aided drug design (CADD) covering diverse therapeutic classes. Multiple components of Structure-Based Drug Discovery (SBDD) along with its workflow and associated challenges are presented while potential leads for Alzheimer’s disease (AD), antiviral agents, anti-human immunodeficiency virus (HIV) drugs, and leads for Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) disease are discussed in detail. Computational toxicological aspects in drug design and discovery, screening adverse effects, and existing or future in silico tools are highlighted, while a novel in silico tool, RASAR, which can be a major technique for small to big datasets when not much experimental data are present, is presented. The book also introduces the reader to the major drug databases covering drug molecules, chemicals, therapeutic targets, metabolomics, and peptides, which are great resources for drug discovery employing drug repurposing, high throughput, and virtual screening. This volume is a great tool for graduates, researchers, academics, and industrial scientists working in the fields of cheminformatics, bioinformatics, computational biology, and chemistry.

Download or read book Computational Approaches for Identifying Drugs Against Alzheimer s Disease written by Radha Mahendran and published by Anchor Academic Publishing. This book was released on 2017-05 with total page 73 pages. Available in PDF, EPUB and Kindle. Book excerpt: Alzheimer’s disease is the most common form of dementia which is incurable. Although some kinds of memory loss are normal during aging, these are not severe enough to interfere with the level of function. ß-Secretase is an important protease in the pathogenesis of Alzheimer’s disease. Some statine-based peptidomimetics show inhibitory activities to the ß-secretase. To explore the inhibitory mechanism, molecular docking and three-dimensional quantitative structure-activity relationship (3D-QSAR) studies on these analogues were performed. Quantitative structure-activity relationship (QSAR) modeling pertains to the construction of predictive models of biological activities as a function of structural and molecular information of a compound library. The concept of QSAR has typically been used for drug discovery and development and has gained wide applicability for correlating molecular information with not only biological activities but also with other physicochemical properties, which has therefore been termed quantitative structure-property relationship (QSPR). In this study, 3D QSAR and pharmacophore mapping studies were carried out using Accelrys Discovery Studio 2.1. The best nine drugs were selected from the 16 ligands and pharmacophore features were generated.

Download or read book Computational and Experimental Studies in Alzheimer s Disease written by Kunal Bhattacharya and published by CRC Press. This book was released on 2024-03-29 with total page 210 pages. Available in PDF, EPUB and Kindle. Book excerpt: This reference book compiles the recent advances in computational and experimental modelling to screen and manage Alzheimer’s disease. It covers basic etiopathology and various in vitro and in vivo strategies of disease intervention. The book discusses how computer-aided drug design approaches reduce costs and increase biological test efficiency. It reviews the screening for anti-Alzheimer drugs and biomarker analysis of disease inhibitors. The book also explores mechanistic aspects of neurodegeneration and the use of natural products as therapeutics for Alzheimer’s disease. Key features: Elaborates on the computational modelling of protein target inhibitors as anti-Alzheimer’s agents Explains the role of phytomolecules and natural products in Alzheimer’s therapy Reviews preclinical ways to assess drugs focusing on Alzheimer’s disease Covers biomarker analysis for Alzheimer’s disease Discusses the onset and progression of Alzheimer’s disease The book is meant for professionals, researchers, and students of neuroscience, psychology, and computational neurosciences.

Download or read book Computational Modeling of Anti aggregation Effect of Non steroidal Anti inflammatory Drugs in Alzheimer s Amyloidogenesis written by Wenling Eileen Chang and published by . This book was released on 2011 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Alzheimer's disease (AD) represents a growing biomedical, social, and economical problem. Millions of people have suffered from the disease globally. Studies have shown that aggregated forms of amyloid [beta] peptide adversely affect neuronal function and may represent the causative agent in AD. It has been demonstrated that chronic treatment with ibuprofen and naproxen reduces the risk of AD and improves the behavioral impairment for patients with AD. This dissertation utilizes high performance parallel computing, all-atom molecular dynamics simulation, and protein-ligand docking to understand the mechanism of the anti-aggregation effect of ibuprofen and naproxen in Alzheimer's amyloidogenesis. The results reveal different mechanisms of ligand binding to the monomers and fibrils formed by A[beta] peptides implicated in AD. Binding to A[beta] monomers is mostly governed by ligand-amino acid interactions, whereas binding to the fibril is determined by the fibril surface geometry and interligand interactions. The antiaggregation effect of ibuprofen and naproxen is explained by direct competition between these ligands and incoming A[beta] peptides for binding to the fibril.

Download or read book Molecular Modeling of the Interaction of A with Neuronal Receptors and Computational Design of Drugs Against Alzheimer s Disease written by Noa Maatuk and published by . This book was released on 2014 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Alzheimer s Disease Drug Development written by Jeffrey Cummings and published by Cambridge University Press. This book was released on 2022-03-31 with total page 575 pages. Available in PDF, EPUB and Kindle. Book excerpt: Alzheimer's Disease (AD) is a growing global public health challenge. The development of new therapies is urgently needed, and a complex ecosystem of organizations has grown to facilitate AD drug discovery and development. Masterfully collating information on the drug development ecosystem, this book emphasizes the contributions of each aspect in the pipeline with a uniform approach to chapters, enabling readers to access relevant information quickly. Topics covered include the use of non-clinical laboratory studies, biomarker development, artificial intelligence, design and management of clinical trials, and funding and financing models. Also discussed is the critical role of advocacy fundraising for drug development. With the approval of aducanumab, the function of the ecosystem has become apparent. This is a definitive overview of how the ecosystem works in transferring an AD drug from its discovery in the laboratory through clinical trial testing to regulatory review and eventual marketing.

Download or read book Computational Chemotaxis Models For Neurodegenerative Disease written by William E Schiesser and published by World Scientific Publishing Company. This book was released on 2017-02-24 with total page 172 pages. Available in PDF, EPUB and Kindle. Book excerpt: The mathematical model presented in this book, based on partial differential equations (PDEs) describing attractant-repellent chemotaxis, is offered for a quantitative analysis of neurodegenerative disease (ND), e.g., Alzheimer's disease (AD). The model is a representation of basic phenomena (mechanisms) for diffusive transport and biochemical kinetics that provides the spatiotemporal distribution of components which could explain the evolution of ND, and is offered with the intended purpose of providing a small step toward the understanding, and possible treatment of ND.The format and emphasis of the presentation is based on the following elements:In other words, a methodology for numerical PDE modeling is presented that is flexible, open ended and readily implemented on modest computers. If the reader is interested in an alternate model, it might possibly be implemented by: (1) modifying and/or extending the current model (for example, by adding terms to the PDEs or adding additional PDEs), or (2) using the reported routines as a prototype for the model of interest.These suggestions illustrate an important feature of computer-based modeling, that is, the readily available procedure of numerically experimenting with a model. The current model is offered as only a first step toward the resolution of this urgent medical problem.

Download or read book Computational Biology in Drug Discovery and Repurposing written by Rajani Sharma and published by CRC Press. This book was released on 2024-08-16 with total page 478 pages. Available in PDF, EPUB and Kindle. Book excerpt: This new book takes an in-depth look at the emerging and prospective field of computational biology and bioinformatics, which possesses the ability to analyze large accumulated biological data collected from sequence analysis of proteins and genes and cell population with an aim to make new predictions pertaining to drug discovery and new biology. The book explains the basic methodology associated with a bioinformatics and computational approach in drug designing. It then goes on to cover the implementation of computational programming, bioinformatics, pharmacophore modeling, biotechnological techniques, and pharmaceutical chemistry in designing drugs. The major advantage of intervention of computer language or programming is to cut down the number of steps and costs in the field of drug designing, reducing the repeating steps and saving time in screening the potent component for drug or vaccine designing. The book describes algorithms used for drug designing and the use of machine learning and AI in drug delivery and disease diagnosis, which are valuable in clinical decision-making. The implementation of robotics in different diseases like stroke, cancer, COVID-19, etc. is also addressed. Topics include machine learning, AI, databases in drug design, molecular docking, bioinformatics tools, target-based drug design, and immunoinformatics, chemoinformatics, and nanoinformatics in drug design. Drug repurposing in drug design in general as well as for specific diseases, including cancer, Alzheimer’s disease, tuberculosis, COVID-19, etc., is also addressed in depth.

Download or read book Integrated Computational Drug Discovery Approaches for Neuropsychiatric Disorders written by Mengshi Zhou and published by . This book was released on 2020 with total page 199 pages. Available in PDF, EPUB and Kindle. Book excerpt: Neuropsychiatric disorders (NPDs) such as Alzheimer's disease (AD) lead to enormous societal burdens. Current treatments of NPDs have limitations, and the drug development process is at a standstill. In this dissertation, we proposed integrated computational approaches to facilitate NPDs drug discovery. First, we developed data-driven system approaches to identify FDA-approved drugs that may target NPDs-related genes. We developed a novel network-based model for drug-target interaction (DTI) prediction by preserving context-specific drug-side effect relationships. Our new network model improved DTI prediction comparing to the traditional similarity-based network model. Furthermore, we extended our model by modeling 855,904 phenotypic and genetic relationships among 24,600 biomedical entities and constructed a DTI prediction system (TargetPredict). Next, TargetPredict was used to identify the FDA-approved drugs that may target AD-associated genes. The AD drugs identified by TargetPredict were associated with lower risks of AD and dementia in electronic health record (EHR) data of 17 million patients over 65 years old. Second, we developed a phenome-driven computational drug repositioning approach to identify NPDs treatments without known NPDs-related genes. Our approach hypothesized that similar drugs treat the same diseases. We applied the approach to Drug addiction (DA), assuming that new treatments share similar phenotypes and common targets with drugs that cause or treat DA. Our method could prioritize FDA-approved and not-yet-approved DA drugs. The top-ranked DA drug candidates may play a beneficial role regarding remission from dependence in 326,340 opioid-dependent patients' EHR data. The pathway-enrichment analysis supported this clinical observation. Third, we performed an EHRs-based retrospective case-control study of 56 million adults (age ≥ 18 years) to study the relationships between tumor necrosis factor (TNF)-mediated systemic inflammation and AD, and the potential of using anti-TNF drugs as AD treatments. We found the co-morbid inflammatory disease involving TNF was associated with an increased risk of AD, and this could be mitigated from the treatment of a TNF blocking agent. In conclusion, our studies, including computational drug target prediction, drug repositioning, and retrospective clinical corroboration, can rapidly identify anti-NPDs drug candidates. Those drug candidates will allow biomedical researchers to conduct hypothesis-driven functional studies in experimental models for NPDs.

Download or read book Improving and Accelerating Therapeutic Development for Nervous System Disorders written by Institute of Medicine and published by National Academies Press. This book was released on 2014-02-06 with total page 107 pages. Available in PDF, EPUB and Kindle. Book excerpt: Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.

Download or read book Drug like Properties Concepts Structure Design and Methods written by Li Di and published by Elsevier. This book was released on 2010-07-26 with total page 549 pages. Available in PDF, EPUB and Kindle. Book excerpt: Of the thousands of novel compounds that a drug discovery project team invents and that bind to the therapeutic target, typically only a fraction of these have sufficient ADME/Tox properties to become a drug product. Understanding ADME/Tox is critical for all drug researchers, owing to its increasing importance in advancing high quality candidates to clinical studies and the processes of drug discovery. If the properties are weak, the candidate will have a high risk of failure or be less desirable as a drug product. This book is a tool and resource for scientists engaged in, or preparing for, the selection and optimization process. The authors describe how properties affect in vivo pharmacological activity and impact in vitro assays. Individual drug-like properties are discussed from a practical point of view, such as solubility, permeability and metabolic stability, with regard to fundamental understanding, applications of property data in drug discovery and examples of structural modifications that have achieved improved property performance. The authors also review various methods for the screening (high throughput), diagnosis (medium throughput) and in-depth (low throughput) analysis of drug properties. - Serves as an essential working handbook aimed at scientists and students in medicinal chemistry - Provides practical, step-by-step guidance on property fundamentals, effects, structure-property relationships, and structure modification strategies - Discusses improvements in pharmacokinetics from a practical chemist's standpoint

Download or read book Natural Product based Synthetic Drug Molecules in Alzheimer s Disease written by Abha Sharma and published by Springer Nature. This book was released on 2024-01-16 with total page 447 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book illustrates the importance of natural products as the source for the development of novel drugs for the treatment of neurodegenerative disorders, including Alzheimer's disease. It also highlights the role of reactive oxygen species and altered metal homeostasis in the progression of Alzheimer’s disease and examines the potential of antioxidants and anti-chelating agents in the clinical intervention of neurodegenerative diseases. The book also discusses the role of neuroinflammation in the pathogenesis of Alzheimer’s disease. The chapters provide information about the drug targets, progress in the development of natural product-based therapeutics, biomarkers, fluorescent diagnostic tools, and theranostic for Alzheimer's disease. The book also provides information about the design and synthesis of natural product-based derivatives against the various targets of Alzheimer's disease including epigenetic targets and the metal dyshomeostasis hypothesis. Cutting across different disciplines, this book is a valuable source for neuroscientists, chemical biologists, pharmaceutical researchers, and synthetic biologists.

Download or read book Computational Approaches Drug Discovery and Design in Medicinal Chemistry and Bioinformatics written by Marco Tutone and published by . This book was released on 2021 with total page 387 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is a collection of original research articles in the field of computer-aided drug design. It reports the use of current and validated computational approaches applied to drug discovery as well as the development of new computational tools to identify new and more potent drugs.

Download or read book Computational Chemotaxis Models for Neurodegenerative Disease written by W. E. Schiesser and published by . This book was released on 2017 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Computational Models of Brain and Behavior written by Ahmed A. Moustafa and published by John Wiley & Sons. This book was released on 2017-09-11 with total page 588 pages. Available in PDF, EPUB and Kindle. Book excerpt: A comprehensive Introduction to the world of brain and behavior computational models This book provides a broad collection of articles covering different aspects of computational modeling efforts in psychology and neuroscience. Specifically, it discusses models that span different brain regions (hippocampus, amygdala, basal ganglia, visual cortex), different species (humans, rats, fruit flies), and different modeling methods (neural network, Bayesian, reinforcement learning, data fitting, and Hodgkin-Huxley models, among others). Computational Models of Brain and Behavior is divided into four sections: (a) Models of brain disorders; (b) Neural models of behavioral processes; (c) Models of neural processes, brain regions and neurotransmitters, and (d) Neural modeling approaches. It provides in-depth coverage of models of psychiatric disorders, including depression, posttraumatic stress disorder (PTSD), schizophrenia, and dyslexia; models of neurological disorders, including Alzheimer’s disease, Parkinson’s disease, and epilepsy; early sensory and perceptual processes; models of olfaction; higher/systems level models and low-level models; Pavlovian and instrumental conditioning; linking information theory to neurobiology; and more. Covers computational approximations to intellectual disability in down syndrome Discusses computational models of pharmacological and immunological treatment in Alzheimer's disease Examines neural circuit models of serotonergic system (from microcircuits to cognition) Educates on information theory, memory, prediction, and timing in associative learning Computational Models of Brain and Behavior is written for advanced undergraduate, Master's and PhD-level students—as well as researchers involved in computational neuroscience modeling research.

Download or read book Computer Aided Drug Design written by Dev Bukhsh Singh and published by Springer Nature. This book was released on 2020-10-09 with total page 308 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides up-to-date information on bioinformatics tools for the discovery and development of new drug molecules. It discusses a range of computational applications, including three-dimensional modeling of protein structures, protein-ligand docking, and molecular dynamics simulation of protein-ligand complexes for identifying desirable drug candidates. It also explores computational approaches for identifying potential drug targets and for pharmacophore modeling. Moreover, it presents structure- and ligand-based drug design tools to optimize known drugs and guide the design of new molecules. The book also describes methods for identifying small-molecule binding pockets in proteins, and summarizes the databases used to explore the essential properties of drugs, drug-like small molecules and their targets. In addition, the book highlights various tools to predict the absorption, distribution, metabolism, excretion (ADME) and toxicity (T) of potential drug candidates. Lastly, it reviews in silico tools that can facilitate vaccine design and discusses their limitations.